GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+10.92%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$300M
AUM Growth
+$300M
(+25%)
Cap. Flow
+$49.7M
Cap. Flow
% of AUM
16.56%
Top 10 Holdings %
Top 10 Hldgs %
36%
Holding
97
New
35
Increased
14
Reduced
13
Closed
29
Top Buys
| 1 |
Biogen
BIIB
|
$12.1M |
| 2 |
Intuitive Surgical
ISRG
|
$9.69M |
| 3 |
ENDP
Endo International plc
ENDP
|
$9.56M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$9.04M |
| 5 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$8.07M |
Top Sells
| 1 |
Zimmer Biomet
ZBH
|
$11.8M |
| 2 |
Community Health Systems
CYH
|
$7.84M |
| 3 |
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
|
$6.94M |
| 4 |
CELG
Celgene Corp
CELG
|
$6.92M |
| 5 |
DYAX
DYAX CORPORATION
DYAX
|
$5.86M |
Sector Composition
| 1 | Healthcare | 88.02% |
| 2 | Financials | 1.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $13.7M | 4.43% | 45,000 +10,000 | +29% | +$3.03M |
|
|
AVDL
2
Avadel Pharmaceuticals
AVDL
$1.43B
| $12.2M | 3.95% | 575,000 +375,000 | +188% | +$7.95M |
|
|
3
Biogen
BIIB
$19.4B
| $12.1M | 3.93% | +30,000 | New | +$12.1M |
|
|
NUVA
4
DELISTED
NuVasive, Inc.
NUVA
| $11.1M | 3.61% | 235,000 +75,000 | +47% | +$3.55M |
|
5
Alnylam Pharmaceuticals
ALNY
$58.5B
| $10.8M | 3.5% | 90,000 +50,000 | +125% | +$5.99M |
|
|
FPRX
6
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $10.6M | 3.42% | 425,000 +325,000 | +325% | +$8.07M |
|
|
7
Intuitive Surgical
ISRG
$170B
| $9.69M | 3.14% | +20,000 | New | +$9.69M |
|
|
ENDP
8
DELISTED
Endo International plc
ENDP
| $9.56M | 3.1% | +120,000 | New | +$9.56M |
|
|
GWPH
9
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $9.21M | 2.99% | 75,000 +30,000 | +67% | +$3.69M |
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $9.04M | 2.93% | +50,000 | New | +$9.04M |
|
|
PTLA
11
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $7.74M | 2.51% | 170,000 -10,000 | -6% | -$456K |
|
12
Vertex Pharmaceuticals
VRTX
$100B
| $7.41M | 2.4% | +60,000 | New | +$7.41M |
|
|
HZNP
13
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $6.95M | 2.25% | +200,000 | New | +$6.95M |
|
|
GNMK
14
DELISTED
GenMark Diagnostics, Inc
GNMK
| $6.8M | 2.2% | +750,000 | New | +$6.8M |
|
|
NSTG
15
DELISTED
NanoString Technologies, Inc.
NSTG
| $6.17M | 2% | 400,000 +65,000 | +19% | +$1M |
|
16
Esperion Therapeutics
ESPR
$448M
| $6.13M | 1.99% | +75,000 | New | +$6.13M |
|
|
CPHD
17
DELISTED
Cepheid Inc
CPHD
| $6.12M | 1.98% | 100,000 +25,000 | +33% | +$1.53M |
|
18
Cigna
CI
$80.3B
| $6.08M | 1.97% | +37,500 | New | +$6.08M |
|
|
EPZM
19
DELISTED
Epizyme, Inc
EPZM
| $6M | 1.94% | 250,000 +135,000 | +117% | +$3.24M |
|
20
Neurocrine Biosciences
NBIX
$13.8B
| $5.85M | 1.9% | +122,500 | New | +$5.85M |
|
21
Amicus Therapeutics
FOLD
$2.34B
| $5.31M | 1.72% | 375,000 +25,000 | +7% | +$354K |
|
22
Atara Biotherapeutics
ATRA
$84.6M
| $5.28M | 1.71% | +100,000 | New | +$5.28M |
|
23
DexCom
DXCM
$29.5B
| $5.2M | 1.68% | +65,000 | New | +$5.2M |
|
|
AET
24
DELISTED
Aetna Inc
AET
| $5.1M | 1.65% | +40,000 | New | +$5.1M |
|
|
ANAC
25
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $5.03M | 1.63% | +65,000 | New | +$5.03M |
|